The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry)
Aim – to analyze long-term results of intensive treatment initiated at rheumatoid arthritis (RA) onset in real clinical practice.Material and methods. 93 RA patients were included. Subcutaneous MTX was initiated at 10–15 mg per week with further dose escalation up to 20–30 mg per week. If MTX monoth...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-07-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3037 |
id |
doaj-6e0b068a9ad8491c8fd3f968792609cd |
---|---|
record_format |
Article |
spelling |
doaj-6e0b068a9ad8491c8fd3f968792609cd2021-08-02T09:05:55ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-07-0159326927410.47360/1995-4484-2021-269-2742713The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry)V. V. Rybakova0A. S. Avdeeva1D. A. Dibrov2E. L. Nasonov3V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Aim – to analyze long-term results of intensive treatment initiated at rheumatoid arthritis (RA) onset in real clinical practice.Material and methods. 93 RA patients were included. Subcutaneous MTX was initiated at 10–15 mg per week with further dose escalation up to 20–30 mg per week. If MTX monotherapy did not allow to achieve treatment target of remission or low disease activity, biologics were added.Results. Against the background of observation, there was a significant decrease in the activity of diseases and the level of acute phase indicators, after 12 months of treatment, the values of the DAS28-ESR indices were 2.76 [2; 3.7], SDAI – 5.34 [1.8; 9.7], CDAI – 5 [1.5; 9.5], corresponded to low disease activity; remission was achieved in 48.6%, low activity – in 17.5%, moderate activity remained in 31%, high activity – in 2.7% of patients. After 6 years the median age of patients was 58 [49; 66] years, the disease duration – 84 [79; 89] months, the low disease activity was documented in 21.3%, and remission – in 7.8% of patients. After 6 years, the value of the activity indices was: DAS28 – 4 [3.4; 4.59], SDAI – 15.06 [9.32; 21], CDAI – 15 [9; 21]; remission – in 7.7%, low disease activity – in 21.1%, moderate activity – in 60%, high activity – in 11.1% of patients.Conclusion. Intensive therapy initiated at RA onset demonstrates high effectiveness, allowing to achieve remission/low disease activity in about 30% of patients. Adherence to this strategy allowed to discontinue biologics in and synthetic DMARDs after achieving treatment target.https://rsp.mediar-press.net/rsp/article/view/3037rheumatoid arthritisorel registryreal clinical practice |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
V. V. Rybakova A. S. Avdeeva D. A. Dibrov E. L. Nasonov |
spellingShingle |
V. V. Rybakova A. S. Avdeeva D. A. Dibrov E. L. Nasonov The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry) Научно-практическая ревматология rheumatoid arthritis orel registry real clinical practice |
author_facet |
V. V. Rybakova A. S. Avdeeva D. A. Dibrov E. L. Nasonov |
author_sort |
V. V. Rybakova |
title |
The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry) |
title_short |
The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry) |
title_full |
The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry) |
title_fullStr |
The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry) |
title_full_unstemmed |
The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry) |
title_sort |
impact of t2t therapy on the treatment of the patients with the early rheumatoid arthritis (data from orel registry) |
publisher |
IMA-PRESS LLC |
series |
Научно-практическая ревматология |
issn |
1995-4484 1995-4492 |
publishDate |
2021-07-01 |
description |
Aim – to analyze long-term results of intensive treatment initiated at rheumatoid arthritis (RA) onset in real clinical practice.Material and methods. 93 RA patients were included. Subcutaneous MTX was initiated at 10–15 mg per week with further dose escalation up to 20–30 mg per week. If MTX monotherapy did not allow to achieve treatment target of remission or low disease activity, biologics were added.Results. Against the background of observation, there was a significant decrease in the activity of diseases and the level of acute phase indicators, after 12 months of treatment, the values of the DAS28-ESR indices were 2.76 [2; 3.7], SDAI – 5.34 [1.8; 9.7], CDAI – 5 [1.5; 9.5], corresponded to low disease activity; remission was achieved in 48.6%, low activity – in 17.5%, moderate activity remained in 31%, high activity – in 2.7% of patients. After 6 years the median age of patients was 58 [49; 66] years, the disease duration – 84 [79; 89] months, the low disease activity was documented in 21.3%, and remission – in 7.8% of patients. After 6 years, the value of the activity indices was: DAS28 – 4 [3.4; 4.59], SDAI – 15.06 [9.32; 21], CDAI – 15 [9; 21]; remission – in 7.7%, low disease activity – in 21.1%, moderate activity – in 60%, high activity – in 11.1% of patients.Conclusion. Intensive therapy initiated at RA onset demonstrates high effectiveness, allowing to achieve remission/low disease activity in about 30% of patients. Adherence to this strategy allowed to discontinue biologics in and synthetic DMARDs after achieving treatment target. |
topic |
rheumatoid arthritis orel registry real clinical practice |
url |
https://rsp.mediar-press.net/rsp/article/view/3037 |
work_keys_str_mv |
AT vvrybakova theimpactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT asavdeeva theimpactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT dadibrov theimpactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT elnasonov theimpactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT vvrybakova impactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT asavdeeva impactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT dadibrov impactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry AT elnasonov impactoft2ttherapyonthetreatmentofthepatientswiththeearlyrheumatoidarthritisdatafromorelregistry |
_version_ |
1721235525804752896 |